肿瘤细胞治疗研究
英文原题:Osteosarcoma cell death induced by innovative scaffolds doped with chemotherapeutics.
Osteosarcoma cell death induced by innovative scaffolds doped with chemotherapeutics.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
骨肉瘤(OS)的治疗包括全身化疗和手术切除。近年来提出了新型治疗方法,利用药物递送系统减少非靶部位副作用并提高疗效。局部递送抗癌化合物可实现较高局部药物浓度,增强肿瘤杀伤、降低耐药并限制全身作用。
本研究提出合成可注射锶掺杂磷酸钙(SrCPC)支架作为药物递送系统,通过可控释放甲氨蝶呤(MTX)或多柔比星(DOX),同时实现骨组织再生和抗癌治疗,分别记为SrCPC-MTX和SrCPC-DOX。研究在人体OS细胞系SAOS-2、工程化OS细胞系SAOS-2-eGFP及U2-OS体外模型中测试载药骨水泥。通过分析细胞增殖和Caspase-3/7活性,分别评估掺杂支架诱导OS细胞死亡和凋亡的能力。为确定在掺杂支架上生长的OS细胞迁移和侵袭能力是否改变,研究开展了伤口愈合实验。
此外,研究采用人脂肪来源间充质干细胞评估SrCPC材料的成骨潜能。成骨标志物评估包括:(i)通过茜素红染色检测矿化基质沉积;(ii)通过酶联免疫吸附测定检测骨钙素(OCN)蛋白表达;(iii)通过实时聚合酶链式反应阵列研究成骨过程。该递送系统在截至第7天的观察中,对OS细胞系产生细胞毒性杀伤并诱导凋亡。SrCPC显示良好的细胞相容性,并上调参与骨骼发育通路的成骨基因,同时增加OCN蛋白表达和矿化基质沉积。基于纳米结构仿生载药骨水泥局部、持续释放抗癌药物的策略,为结合骨再生和局部抗癌治疗的未来疗法提供了有前景的方法。
Osteosarcoma (OS) cancer treatments include systemic chemotherapy and surgical resection. In the last years, novel treatment approaches have been proposed, which employ a drug-delivery system to prevent offside effects and improves treatment efficacy. Locally delivering anticancer compounds improves on high local concentrations with more efficient tumour-killing effect, reduced drugs resistance and confined systemic effects.
Here, the synthesis of injectable strontium-doped calcium phosphate (SrCPC) scaffold was proposed as drug delivery system to combine bone tissue regeneration and anticancer treatment by controlled release of methotrexate (MTX) and doxorubicin (DOX), coded as SrCPC-MTX and SrCPC-DOX, respectively.
The drug-loaded cements were tested in an in vitro model of human OS cell line SAOS-2, engineered OS cell line (SAOS-2-eGFP) and U2-OS. The ability of doped scaffolds to induce OS cell death and apoptosis was assessed analysing cell proliferation and Caspase-3/7 activities, respectively. To determine if OS cells grown on doped-scaffolds change their migratory ability and invasiveness, a wound-healing assay was performed.
In addition, the osteogenic potential of SrCPC material was evaluated using human adipose derived-mesenchymal stem cells. Osteogenic markers such as (i) the mineral matrix deposition was analysed by alizarin red staining; (ii) the osteocalcin (OCN) protein expression was investigated by enzyme-linked immunosorbent assay test, and (iii) the osteogenic process was studied by real-time polymerase chain reaction array. The delivery system induced cell-killing cytotoxic effects and apoptosis in OS cell lines up to Day 7.
SrCPC demonstrates a good cytocompatibility and it induced upregulation of osteogenic genes involved in the skeletal development pathway, together with OCN protein expression and mineral matrix deposition. The proposed approach, based on the local, sustained release of anticancer drugs from nanostructured biomimetic drug-loaded cements is promising for future therapies aiming to combine bone regeneration and anticancer local therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。